Literature DB >> 9619770

Simultaneous HLA Class I and Class II antibodies screening with flow cytometry.

R Pei1, G Wang, C Tarsitani, S Rojo, T Chen, S Takemura, A Liu, J Lee.   

Abstract

A flow cytometric method of simultaneously screening both HLA Class I and Class II panel reactive antibodies (PRA) was developed using a pool of 30 different Class I and 30 different Class II microbeads coated with purified HLA antigens. The antibodies in the serum that react specifically to the coated HLA antigens are detected by using a FITC-conjugated antibody against human IgG. Percent PRA can be determined by the percentage of microbeads that react positively to the serum. There is no cross-reactivity between the Class I and Class II microbeads. A mixture of Class I and Class II microbeads can be distinguished by their different fluorescent properties on the flow cytometry analysis. Thus, both Class I and Class II PRA can be detected from a single tube reaction.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9619770     DOI: 10.1016/s0198-8859(98)00020-2

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  30 in total

1.  Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.

Authors:  A D Kirk; A Guasch; H Xu; J Cheeseman; S I Mead; A Ghali; A K Mehta; D Wu; H Gebel; R Bray; J Horan; L S Kean; C P Larsen; T C Pearson
Journal:  Am J Transplant       Date:  2014-03-31       Impact factor: 8.086

Review 2.  [Alloantibodies-mediated kidney transplant rejection: a pair of continuing approaches, and with nonetheless many open questions].

Authors:  Georg Böhmig
Journal:  Wien Klin Wochenschr       Date:  2006-07       Impact factor: 1.704

Review 3.  HLA antibody analysis: sensitivity, specificity, and clinical significance in solid organ transplantation.

Authors:  Adriana Zeevi; Alin Girnita; Rene Duquesnoy
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 4.  Leukocyte antigen and antibody detection assays: tools for assessing and preventing pulmonary transfusion reactions.

Authors:  David F Stroncek; Emmanuel Fadeyi; Sharon Adams
Journal:  Transfus Med Rev       Date:  2007-10

5.  Analysis of a high-throughput HLA antibody screening assay for use with platelet donors.

Authors:  Emmanuel Fadeyi; Sharon Adams; Brett Peterson; Julia Hackett; Phyllis Byrne; Harvey G Klein; Francesco M Marincola; Susan F Leitman; David F Stroncek
Journal:  Transfusion       Date:  2008-04-15       Impact factor: 3.157

6.  Class II alloantibody and mortality in simultaneous liver-kidney transplantation.

Authors:  J G O'Leary; H M Gebel; R Ruiz; R A Bray; J D Marr; X J Zhou; S M Shiller; B M Susskind; A D Kirk; G B Klintmalm
Journal:  Am J Transplant       Date:  2013-02-22       Impact factor: 8.086

7.  Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.

Authors:  Lionel Rostaing; Pablo Massari; Valter Duro Garcia; Eduardo Mancilla-Urrea; Georgy Nainan; Maria del Carmen Rial; Steven Steinberg; Flavio Vincenti; Rebecca Shi; Greg Di Russo; Dolca Thomas; Josep Grinyó
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-04       Impact factor: 8.237

8.  Persistence of lymphocytotoxic antibodies in patients in the trial to reduce alloimmunization to platelets: implications for using modified blood products.

Authors:  Sherrill J Slichter; Douglas Bolgiano; Kuo-Jang Kao; Thomas S Kickler; Janice McFarland; Jeffrey McCullough; Robert Woodson
Journal:  Transfus Med Rev       Date:  2011-02-23

Review 9.  Transplant immuno-diagnostics: crossmatch and antigen detection.

Authors:  Andrew M South; Paul C Grimm
Journal:  Pediatr Nephrol       Date:  2015-07-03       Impact factor: 3.714

10.  Circulating anti-endothelial cell antibodies are associated with poor outcome in renal allograft recipients with acute rejection.

Authors:  Qiquan Sun; Zhihong Liu; Jinsong Chen; Huiping Chen; Jiqiu Wen; Dongrui Cheng; Leishi Li
Journal:  Clin J Am Soc Nephrol       Date:  2008-06-25       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.